CENTURY THERAPEUTICS INC (IPSC) Stock Price, Quote, News and Overview
NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD
IPSC Quote, Performance and Key Statistics
CENTURY THERAPEUTICS INC
NASDAQ:IPSC (2/10/2025, 8:07:01 PM)
After market: 0.725 +0 (+0.43%)0.7219
0 (-0.48%)
The current stock price of IPSC is 0.7219 USD. In the past month the price decreased by -27.08%. In the past year, price decreased by -84.64%.
IPSC Latest News and Analysis
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at...
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
IPSC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.81 | 336.36B | ||
| AMGN | AMGEN INC | 14.87 | 158.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1620.59 | 121.03B | ||
| GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.73 | 20.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Related stock screener links
About IPSC
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 152 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Company Info
CENTURY THERAPEUTICS INC
25 N 38Th Street, 11Th Floor
PHILADELPHIA PENNSYLVANIA US
CEO: Osvaldo Flores
Employees: 152
Company Website: https://www.centurytx.com/
Investor Relations: http://investors.centurytx.com
Phone: 12159814000
IPSC FAQ
What is the stock price of IPSC?
The current stock price of IPSC is 0.7219 USD.
What is the symbol for CENTURY THERAPEUTICS INC stock?
The exchange symbol of CENTURY THERAPEUTICS INC is IPSC and it is listed on the Nasdaq exchange.
On which exchange is IPSC stock listed?
IPSC stock is listed on the Nasdaq exchange.
Is IPSC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IPSC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IPSC.
Does IPSC stock pay dividends?
IPSC does not pay a dividend.
What is the Price/Earnings (PE) ratio of IPSC?
IPSC does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
What is the Short Interest ratio of IPSC stock?
The outstanding short interest for IPSC is 5.02% of its float.
IPSC Technical Analysis
IPSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IPSC. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability.
IPSC Financial Highlights
Over the last trailing twelve months IPSC reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS decreased by 15.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.42% | ||
| ROE | -66.38% | ||
| Debt/Equity | 0 |
IPSC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to IPSC. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 27.64% and a revenue growth 89.46% for IPSC